Добірка наукової літератури з теми "Lung wound repair"

The mechanisms that enable and regulate alveolar type II (AT II) epithelial cell wound healing in vitro and in vivo remain largely unknown and need further elucidation. We used an in silico AT II cell-mimetic analogue to explore and better understand plausible wound healing mechanisms for two conditions: cyst repair in three-dimensional cultures and monolayer wound healing. Starting with the analogue that validated for key features of AT II cystogenesis in vitro , we devised an additional cell rearrangement action enabling cyst repair. Monolayer repair was enabled by providing ‘cells’ a control mechanism to switch automatically to a repair mode in the presence of a distress signal. In cyst wound simulations, the revised analogue closed wounds by adhering to essentially the same axioms available for alveolar-like cystogenesis. In silico cell proliferation was not needed. The analogue recovered within a few simulation cycles but required a longer recovery time for larger or multiple wounds. In simulated monolayer wound repair, diffusive factor-mediated ‘cell’ migration led to repair patterns comparable to those of in vitro cultures exposed to different growth factors. Simulations predicted directional cell locomotion to be critical for successful in vitro wound repair. We anticipate that with further use and refinement, the methods used will develop as a rigorous, extensible means of unravelling mechanisms of lung alveolar repair and regeneration.

Abnormal alveolar wound repair contributes to the development of pulmonary fibrosis after lung injury. Hepatocyte growth factor (HGF) is a potent mitogenic factor for alveolar epithelial cells and may therefore improve alveolar epithelial repair in vitro and in vivo. We hypothesized that HGF could increase alveolar epithelial repair in vitro and improve pulmonary fibrosis in vivo. Alveolar wound repair in vitro was determined using an epithelial wound repair model with HGF-transfected A549 alveolar epithelial cells. Electroporation-mediated, nonviral gene transfer of HGF in vivo was performed 7 days after bleomycin-induced lung injury in the rat. Alveolar epithelial repair in vitro was increased after transfection of wounded epithelial monolayers with a plasmid encoding human HGF, pCikhHGF [human HGF (hHGF) gene expressed from the cytomegalovirus (CMV) immediate-early promoter and enhancer] compared with medium control. Electroporation-mediated in vivo HGF gene transfer using pCikhHGF 7 days after intratracheal bleomycin reduced pulmonary fibrosis as assessed by histology and hydroxyproline determination 14 days after bleomycin compared with controls treated with the same vector not containing the HGF sequence (pCik). Lung epithelial cell proliferation was increased and apoptosis reduced in hHGF-treated lungs compared with controls, suggesting increased alveolar epithelial repair in vivo. In addition, profibrotic transforming growth factor-β1 (TGF-β1) was decreased in hHGF-treated lungs, indicating an involvement of TGF-β1 in hHGF-induced reduction of lung fibrosis. In conclusion, electroporation-mediated gene transfer of hHGF decreases bleomycin-induced pulmonary fibrosis, possibly by increasing alveolar epithelial cell proliferation and reducing apoptosis, resulting in improved alveolar wound repair.

Abstract The incidence of pulmonary infection is elevated in patients with traumatic injury, and the severity of disease, morbidity, and mortality is positively correlated with the degree of trauma. While this clinical problem is well documented, its mechanistic basis is not well understood. Current models are designed to assess the effect of trauma on the development of pneumonia, but lack the ability to measure the subsequent effect of lung infection on wound repair. We have established a model that allows for the simultaneous assessment of wound healing and lung responses in mice with surgical wounds and Influenza A virus (IAV) infection. Mice are wounded by the subcutaneous implantation of sterile polyvinyl alcohol (PVA) sponges or by excision of tail skin and infected with IAV 24 hours later. PVA sponge implantation allows for the assessment of cellular and cytokine responses to injury, while excisional tail wounding allows for the measurement of rate of repair. Our data demonstrate that IAV infection results in delayed wound repair. Furthermore, the wounds of infected mice have lower repair cytokine concentrations and decreased cellularity, mediated in part by impaired trafficking of Ly6Chi monocytes. Wounded mice with IAV infection also have elevated concentrations of proinflammatory cytokines and chemokines in the serum and bronchoalveolar lavage fluid, suggesting an inflated systemic inflammatory response. Taken together, these data indicate that the presence of viral lung infection impairs the normal progression of wound repair. Future studies will determine whether this effect is specific to viral infection, or whether other lung injuries including pulmonary bacterial infection have a similar effect on wound repair responses.

As part of the innate immune defense, the polarized conducting lung epithelium acts as a barrier to keep particulates carried in respiration from underlying tissue. Arsenic is a metalloid toxicant that can affect the lung via inhalation or ingestion. We have recently shown that chronic exposure of mice or humans to arsenic (10–50 ppb) in drinking water alters bronchiolar lavage or sputum proteins consistent with reduced epithelial cell migration and wound repair in the airway. In this report, we used an in vitro model to examine effects of acute exposure of arsenic (15–290 ppb) on conducting airway lung epithelium. We found that arsenic at concentrations as low as 30 ppb inhibits reformation of the epithelial monolayer following scrape wounds of monolayer cultures. In an effort to understand functional contributions to epithelial wound repair altered by arsenic, we showed that acute arsenic exposure increases activity and expression of matrix metalloproteinase (MMP)-9, an important protease in lung function. Furthermore, inhibition of MMP-9 in arsenic-treated cells improved wound repair. We propose that arsenic in the airway can alter the airway epithelial barrier by restricting proper wound repair in part through the upregulation of MMP-9 by lung epithelial cells.

Reactive oxygen species (ROS) are released into the alveolar space and contribute to alveolar epithelial damage in patients with acute lung injury. However, the role of ROS in alveolar repair is not known. We studied the effect of ROS in our in vitro wound healing model using either human A549 alveolar epithelial cells or primary distal lung epithelial cells. We found that H2O2 inhibited alveolar epithelial repair in a concentration-dependent manner. At similar concentrations, H2O2 also induced apoptosis, an effect seen particularly at the edge of the wound, leading us to hypothesize that apoptosis contributes to H2O2-induced inhibition of wound repair. To learn the role of apoptosis, we blocked caspases with the pan-caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp (zVAD). In the presence of H2O2, zVAD inhibited apoptosis, particularly at the wound edge and, most importantly, maintained alveolar epithelial wound repair. In H2O2-exposed cells, zVAD also maintained cell viability as judged by improved cell spreading and/or migration at the wound edge and by a more normal mitochondrial potential difference compared with cells not treated with zVAD. In conclusion, H2O2 inhibits alveolar epithelial wound repair in large part by induction of apoptosis. Inhibition of apoptosis can maintain wound repair and cell viability in the face of ROS. Inhibiting apoptosis may be a promising new approach to improve repair of the alveolar epithelium in patients with acute lung injury.

Respiratory diseases are frequently characterised by epithelial injury, airway inflammation, defective tissue repair, and airway remodelling. This may occur in a subacute or chronic context, such as asthma and chronic obstructive pulmonary disease, or occur acutely as in pathogen challenge and acute respiratory distress syndrome (ARDS). Despite the frequent challenge of lung homeostasis, not all pulmonary insults lead to disease. Traditionally thought of as a quiescent organ, emerging evidence highlights that the lung has significant capacity to respond to injury by repairing and replacing damaged cells. This occurs with the appropriate and timely resolution of inflammation and concurrent initiation of tissue repair programmes. Airway epithelial cells are key effectors in lung homeostasis and host defence; continual exposure to pathogens, toxins, and particulate matter challenge homeostasis, requiring robust defence and repair mechanisms. As such, the epithelium is critically involved in the return to homeostasis, orchestrating the resolution of inflammation and initiating tissue repair. This review examines the pivotal role of pulmonary airway epithelial cells in initiating and moderating tissue repair and restitution. We discuss emerging evidence of the interactions between airway epithelial cells and candidate stem or progenitor cells to initiate tissue repair as well as with cells of the innate and adaptive immune systems in driving successful tissue regeneration. Understanding the mechanisms of intercellular communication is rapidly increasing, and a major focus of this review includes the various mediators involved, including growth factors, extracellular vesicles, soluble lipid mediators, cytokines, and chemokines. Understanding these areas will ultimately identify potential cells, mediators, and interactions for therapeutic targeting.

There are 190,600 cases of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) each year in the United States, and the incidence and mortality of ALI/ARDS increase dramatically with age. Patients with ALI/ARDS have alveolar epithelial injury, which may be worsened by high-pressure mechanical ventilation. Alveolar type II (ATII) cells are the progenitor cells for the alveolar epithelium and are required to reestablish the alveolar epithelium during the recovery process from ALI/ARDS. Lung fibroblasts (FBs) migrate and proliferate early after lung injury and likely are an important source of growth factors for epithelial repair. However, how lung FBs affect epithelial wound healing in the human adult lung has not been investigated in detail. Hepatocyte growth factor (HGF) is known to be released mainly from FBs and to stimulate both migration and proliferation of primary rat ATII cells. HGF is also increased in lung tissue, bronchoalveolar lavage fluid, and serum in patients with ALI/ARDS. Therefore, we hypothesized that HGF secreted by FBs would enhance wound closure in alveolar epithelial cells (AECs). Wound closure was measured using a scratch wound-healing assay in primary human AEC monolayers and in a coculture system with FBs. We found that wound closure was accelerated by FBs mainly through HGF/c-Met signaling. HGF also restored impaired wound healing in AECs from the elderly subjects and after exposure to cyclic stretch. We conclude that HGF is the critical factor released from FBs to close wounds in human AEC monolayers and suggest that HGF is a potential strategy for hastening alveolar repair in patients with ALI/ARDS.

Biologically active interleukin (IL)-1β is present in the pulmonary edema fluid obtained from patients with acute lung injury and has been implicated as an important early mediator of nonpulmonary epithelial wound repair. Therefore, we tested the hypothesis that IL-1β would enhance wound repair in cultured monolayers from rat alveolar epithelial type II cells. IL-1β (20 ng/ml) increased the rate of in vitro alveolar epithelial repair by 118 ± 11% compared with that in serum-free medium control cells ( P < 0.01). IL-1β induced cell spreading and migration at the edge of the wound but not proliferation. Neutralizing antibodies to epidermal growth factor (EGF) and transforming growth factor-α or inhibition of the EGF receptor by tyrphostin AG-1478 or genistein inhibited IL-1β-induced alveolar epithelial repair, indicating that IL-1β enhances in vitro alveolar epithelial repair by an EGF- or transforming growth factor-α-dependent mechanism. Moreover, the mitogen-activated protein kinase pathway is involved in IL-1β-induced alveolar epithelial repair because inhibition of extracellular signal-regulated kinase activation by PD-98059 inhibited IL-1β-induced alveolar epithelial repair. In conclusion, IL-1β augments in vitro alveolar epithelial repair, indicating a possible novel role for IL-1β in the early repair process of the alveolar epithelium in acute lung injury.

Cystic fibrosis (CF) is an autosomal recessive, life-threatening condition affecting many organs and tissues, the lung disease being the chief cause of morbidity and mortality. Mutations affecting the CF Transmembrane Conductance Regulator (CFTR) gene determine the expression of a dysfunctional protein that, in turn, triggers a pathophysiological cascade, leading to airway epithelium injury and remodeling. In vitro and in vivo studies point to a dysregulated regeneration and wound repair in CF airways, to be traced back to epithelial CFTR lack/dysfunction. Subsequent altered ion/fluid fluxes and/or signaling result in reduced cell migration and proliferation. Furthermore, the epithelial-mesenchymal transition appears to be partially triggered in CF, contributing to wound closure alteration. Finally, we pose our attention to diverse approaches to tackle this defect, discussing the therapeutic role of protease inhibitors, CFTR modulators and mesenchymal stem cells. Although the pathophysiology of wound repair in CF has been disclosed in some mechanisms, further studies are warranted to understand the cellular and molecular events in more details and to better address therapeutic interventions.

Le syndrome de détresse respiratoire aiguë est une cause majeure d'insuffisance respiratoire avec un taux de mortalité élevé. Elle se caractérise par des lésions alvéolaires diffuses, un œdème alvéolaire et une défaillance respiratoire hypoxémique qui entraînent de lourds coûts de santé. Actuellement, les traitements disponibles pour le SDRA restent principalement de soutien, et aucune approche pharmacologique n'est traduite avec succès en application clinique. Il existe deux processus majeurs au cours du développement physiopathologique du SDRA qui conduisent à la formation d'un œdème pulmonaire :dysfonctionnement de la barrière alvéolaire et altération de la clairance du liquide alvéolaire suite à une lésion épithéliale alvéolaire et à une inflammation. Il a été indiqué que le récepteur des produits de glycation avancée (RAGE) était impliqué au cours de ces processus, avec le potentiel élevé de sa forme soluble en tant que biomarqueur pour le diagnostic et le pronostic du SDRA. Les agents halogénés volatils, tels que le sévoflurane ou l'isoflurane, sont de plus en plus utilisés dans les unités de soins intensifs comme agents sédatifs avec leurs caractéristiques intrinsèques idéales en tant que sédatifs. De plus, de nombreuses études précliniques et cliniques indiquent ses effets protecteurs pulmonaires chez les patients atteints de SDRA.Cependant, les mécanismes de ces effets bénéfiques restent à clarifier.Les principaux objectifs de ce travail de thèse sont multiples, à travers des approches expérimentales et modèles translationnels in vivo et in vitro du SDRA,1) Évaluer les effets protecteurs pulmonaires bénéfiques du sévoflurane dans le SDRA, y compris ses effets sur les caractéristiques physiologiques du SDRA, la clairance du liquide pulmonaire et la perméabilité alvéolaire.2) Étudier le mécanisme précis des effets observés du sévoflurane, y compris des études mécanistiques et la fonction et l'expression des protéines impliquées.3) Explorer le rôle de RAGE dans les lésions et la réparation de l'épithélium pulmonaire et son éventuel rôle de médiation des effets bénéfiques du sévoflurane.Au cours de ce travail de thèse, nous avons avancé sous plusieurs angles : Premièrement, nos travaux ont trouvé dans notre modèle de cicatrisation des cellules A549, le rôle important de RAGE dans la réparation des lésions pulmonaires processus, car son ligand, HMGB1, et les AGE ont favorisé la cicatrisation des plaies dépendante de RAGE des cellules épithéliales alvéolaires pulmonaires, ce qui est possiblement expliqué par une migration et une prolifération cellulaires améliorées. Deuxièmement, nos travaux sur des modèles murins de SDRA, trouve une diminution des indices de perméabilité et des structures épithéliales préservées dans les cellules et les souris, au moins en partie, augmentant l'expression de ZO-1 et l'inhibition de l'activité de RhoA et de pMLC ainsi que le réarrangement du cytosquelette d'actine suite à une lésion épithéliale pulmonaire . De plus, RAGE peut jouer un rôle médiateur dans les effets du sévoflurane sur les lésions pulmonaires aiguës. De plus, nos travaux sur des modèles de SDRA porcins in vivo ont confirmé les effets protecteurs pulmonaires du sévoflurane sur les caractéristiques du SDRA, avec une oxygénation améliorée, une perméabilité alvéolaire restaurée et une AFC améliorée. Notre étude suggère que l'effet protecteur du sévoflurane sur l'AFC peut s'expliquer par la restauration de l'expression pulmonaire altérée des canaux épithéliaux AQP-5, Na, K, ATPase et ENaC pendant le SDRA.Dans l'ensemble, ces travaux de thèse expliquent plus précisément les effets protecteurs des agents halogénés et la nouvelle révélation de son mécanisme potentiel, et conforte ainsi le grand intérêt pour l'utilisation de la sédation inhalée en soins intensifs pour les patients atteints de SDRA. Ce travail pourrait donner de nouvelles perspectives pour la recherche sur les effets du sévoflurane sur le SDRA et sa résolution
Acute respiratory distress syndrome (ARDS) is a major cause of respiratory failurewith a high mortality rate. It is characterized by diffuse alveolar damage, alveolar edema, and hypoxemic respiratory loss which cause heavy healthcare costs. Currently, available treatments for ARDS remain primarily supportive, and no pharmacological approach is successfully translated into clinical application. There are two major processes during the physiopathological development of ARDS that lead to the formation of lung edema:alveolar barrier dysfunction and the impairment of alveolar fluid clearance following alveolar epithelial injury and inflammation. The receptor for advanced glycation end products (RAGE) was indicated to be involved during those processes, with the high potential of its soluble form as a biomarker for ARDS diagnostic and prognostic. Volatile halogenated agents, such as sevoflurane or isoflurane, are increasingly used in intensive care units as sedative agents with their ideal intrinsic characteristics as a sedative. Furthermore, numerous pre-clinical and clinical studies indicate its lung protective effects for ARDS patients.However, its mechanisms of such beneficial effects remain to be clarified.The main objectives of this thesis work are multiple, through experimental andtranslational in vivo and in vitro models of ARDS, to1) Asses the beneficial lung protective effects of sevoflurane in ARDS, including its effects on ARDS physiological features, lung fluid clearance, and alveolar permeability.2) Investigate the precise mechanism of observed effects of sevoflurane, including mechanistic studies and involved proteins' function and expression.3) Explore the role of RAGE in lung epithelial injury and repair and its eventualmediation role of the beneficial effects of sevoflurane.During this thesis work, we advanced from many angles: First, our work found in ourA549 cells wound healing model, the important role of RAGE in the lung injury repairprocess, as its ligand, HMGB1, and AGEs promoted RAGE-dependent wound healing oflung alveolar epithelial cells, which is possible through enhanced cell migration and proliferation.Secondly, our work in murine in vitro and in vivo ARDS models, animprovement of experimental features, with decreased indices of permeability and preserved epithelial structures in cells and mice, by at least in a part, increasing expression of ZO-1 and the inhibition of RhoA activity and pMLC as well as actin cytoskeleton rearrangement following lung epithelial injury. Additionally, RAGE may play a mediating role in the effects of sevoflurane on acute lung injury. Furthermore, our work in porcine in vivo ARDS models confirmed the lung protective effects of sevoflurane on ARDS features, with improved oxygenation, restored alveolar permeability, and improved AFC. Our study suggests theprotective effect of sevoflurane on AFC may be explained by the restoration of impaired lung expression of epithelial channels AQP-5, Na, K, ATPase, and ENaC during ARDS.Taken together, this thesis work explained more precisely the protective effects ofhalogenated agents and the new revelation of its potential mechanism, and hence supports the high interest in the use of inhaled sedation in intensive care for ARDS patients. This work may give some new insights for research on the effects of sevoflurane on ARDS and its resolution.Keywords: Acute respiratory distress syndrome; Sevoflurane; Lung epithelial barrierfunction; Lung wound repair; Alveolar fluid clearance; Epithelial channels: Junction proteins;Intracellular pathways; Receptor for advanced glycation end-products

During the early 1950s, several dozen surgeons were attempting to develop technologies and techniques that would allow them to operate inside the heart. The challenge was to develop a safe way to temporarily take over the functions of the heart and lungs so the heart could be opened and drained of blood. A surgeon could then see and repair abnormal or damaged structures inside the organ. The first patients were children or adolescents with congenital heart defects that had caused heart failure. Mayo surgeon John Kirklin led a multidisciplinary team in the testing and clinical use of a heart-lung machine that had been refined in Rochester from plans provided by IBM and John Gibbon Jr. of Philadelphia. Although initial mortality was high, experience with the Mayo-Gibbon machine proved that it was possible to operate inside the hearts and save the lives of patients who were destined to die without surgery.

Abstract When Klara Bergman’s doctors told her that she had incurable lung cancer, she did not question the diagnosis. But she felt it was a terrible injustice. She felt that she had been cheated and was being punished for no good reason. Mrs. Bergman, who was 80 years old, had suffered in Nazi concentration camps during World War II and lost most of her loved ones. She had cared for her sick father for many years after they were freed from the camp. Since then she had strived to repair and alleviate the suffering of victims of concentration camps, never thinking of herself or of her own needs. Why had God inflicted such a terrible injustice on her? A good and loving God would not do such a thing. Perhaps there was no God. All her life she had been deeply religious and committed to her Jewish faith. But if God existed, he was not there for her now.

Abstract A weak motor has no flexibility; under constant stress, it tires quickly. To pull a load, it must always work at maximum output. It will soon end up in the repair shop. There is an analogy with every facet of flute playing: if there exists a choice between weak and strong muscles, the latter must in general be called into action; they are more flexible because they do not operate at full power and therefore tire less. Let us take a few examples. The strong abdominal muscles provide the most important action by releasing the belt and creating a vacuum in the chest cavity. The pectoral and intercostal muscles also come into play. They are weaker, but most of all, their action is in a flat direction and for that reason slower. They must heave the chest and shoulders, which is necessary for a full apnea but inefficient and tiresome for normal breathing, as well as constricting for the throat. This too calls the abdominal muscles into action to push air out. If the pectoral and intercostal muscles were generating pressure at this time, it would be very strenuous and inefficient. Instead, they counteract the energy generated in the abdomen through isometrics. In apnea, they actually prevent the collapse of the shoulders and chest that would empty the lungs under the pressure of abdominal support. It is a sort of passive resistance that they provide (appoggio), much more suited to their nature and essential for air management.